Clinically, strategies that aim to block AR and ER, namely, androgen deprivation therapy and selective ER modulators, are widely employed to treat prostate and breast cancer, respectively, strongly supporting the practicality of NRs as druggable targets to improve cancer treatment outcomes. This evidence concerns the gene AR and breast carcinoma.